Abstract
AIMS: Heart failure-related cardiogenic shock (HF-CS) accounts for about half of CS cases, with a paucity of data regarding the role of kidney injury in this subset. This study aims to evaluate patient characteristics and outcome associated with renal function in patients with HF-CS.
METHODS AND RESULTS: In this multicentre, international, retrospective study, patients with HF-CS from 16 tertiary care centres in five countries were enrolled between 2010 and 2021. To investigate differences in clinical presentation, complications, and 30-day mortality, based on renal function, adjusted logistic and Cox regression models were fitted. Among 1010 HF-CS patients, the median age was 64 (interquartile range [IQR] 52-75) years, with 71.7% being male. Median baseline creatinine was 1.7 (IQR 1.2-2.5) mg/dl, corresponding to an estimated glomerular filtration rate (eGFR) of 41.0 (IQR 25.2-62.2) ml/min/1.73 m2. In patients with acute kidney injury (AKI), 30-day mortality increased with AKI stages (no AKI 41.7%, AKI stage 1 43.3%, AKI stage 2 50.0%, AKI stage 3 63.7%; adjusted hazard ratio [HR] for AKI stage 3 1.97, 95% confidence interval [CI] 1.56-2.48, p < 0.001). Similarly, severe renal dysfunction (eGFR ≤ median) was associated with a 21% higher 30-day mortality risk (61.0% vs. 40.1%; adjusted HR 1.48, 95% CI 1.20-1.84, p < 0.001). Sepsis and bleeding were associated with both AKI and renal dysfunction, even after adjustment.
CONCLUSIONS: In HF-CS, kidney injury is associated with higher 30-day mortality, potentially mediated by bleeding and sepsis. These findings support the consideration of kidney function as a prognostic marker and call for the development and evaluation of kidney-restoring adjunct interventions in HF-CS.
| Original language | English |
|---|---|
| Journal | European Journal of Heart Failure |
| ISSN | 1388-9842 |
| DOIs | |
| Publication status | Published - 2025 |
Funding
| Funders | Funder number |
|---|---|
| AstraZeneca | |
| Novartis | |
| CSL Behring | |
| Cytosorbents | |
| Edwards Lifesciences | |
| Gilead | |
| ADVITOS | |
| Bundesministerium für Bildung und Forschung | |
| Shionogi and Zoll | |
| Bristol Myers Squibb | |
| Daiichi Sankyo | |
| Medical Research Council | |
| Boehringer-Ingelheim | |
| Fondation Leducq | |
| CVRx | |
| Amgen | |
| MSD | |
| Pfizer | |
| trial committee work for Abbott | |
| Bayer | |
| EKFS | |
| British Heart Foundation | PG/20/22/35093, AA/18/2/34218 |
| MAESTRIA | 965286 |
| European Union AFFECT‐AF | 847770 |
| Deutsche Forschungsgemeinschaft | 546376900 |
| Deutsches Zentrum für Herz-Kreislaufforschung | Ki 509167694, DZHK FKZ 81X2800182, 81Z0710110, 81Z0710116 |
Research Areas and Centers
- Centers: Cardiological Center Luebeck (UHZL)
DFG Research Classification Scheme
- 2.22-12 Cardiology, Angiology